Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A
Emma H Urlings, Floor CJI Heubel-Moenen, René van Oerle, Dave LS Hellenbrand, Paola EJ van der Meijden, Tilman M Hackeng, Hugo ten Cate, Magdolna Nagy, Yvonne MC Henskens, Henri MH Spronk · 2026
Read Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A by Emma H Urlings, Floor CJI Heubel-Moenen, René van Oerle, Dave LS Hellenbrand, Paola EJ van der Meijden, Tilman M Hackeng, Hugo ten Cate, Magdolna Nagy, Yvonne MC Henskens, Henri MH Spronk (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13241885.txt.
Description
Emma Urlings and co-authors build a better blood test for following hemophilia A treatment, in a 2026 paper. Patients on the antibody drug emicizumab fool the standard clotting tests, leaving doctors short of a reliable gauge. The team developed a thrombin generation test triggered through the intrinsic pathway, the route the missing factor belongs to, and compared it with tissue-factor versions.
Their reagent stayed silent in plasma lacking the intrinsic factors and answered in a straight line to spiked drug doses. In samples from twenty-two treated patients it was several times more sensitive to drug level changes than the older triggers. The authors offer it for tracking both factor replacement and antibody therapy.
Catalog record
| CREATOR | Emma H Urlings, Floor CJI Heubel-Moenen, René van Oerle, Dave LS Hellenbrand, Paola EJ van der Meijden, Tilman M Hackeng, Hugo ten Cate, Magdolna Nagy, Yvonne MC Henskens, Henri MH Spronk |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |